Alkaline Phosphatase ALPPL-2 Is a Novel Pancreatic Carcinoma-Associated Protein

2013/03/07 by Pooja Dua, Hye Suk Kang, Seung‐Mo Hong +5 · 96 citations
Biochemistry, Genetics and Molecular Biology · #Advanced biosensing and bioanalysis techniques #Aptamer #Biochemistry #Biology #Cancer #Cancer cell #Cancer research #Carcinogenesis #Cell #Cell culture #Gene #Gene knockdown #Genetics #Malignancy #MicroRNA in disease regulation #Molecular biology #Pancreatic cancer #RNA #RNA modifications and cancer #Systematic evolution of ligands by exponential enrichment

paper · doi:10.1158/0008-5472.can-12-3682

published in Cancer Research 73(6), 1934-1945 (American Association for Cancer Research)

openalex publication_date 2013/03/07 · openalex created_date 2025/10/10 · openalex updated_date 2026/07/27

Abstract

Pancreatic ductal adenocarcinoma (PDAC) is a highly aggressive malignancy with a very low median survival rate. The lack of early sensitive diagnostic markers is one of the main causes of PDAC-associated lethality. Therefore, to identify novel pancreatic cancer biomarkers that can facilitate early diagnosis and also help in the development of effective therapeutics, we developed RNA aptamers targeting pancreatic cancer by Cell-systematic evolution of ligands by exponential enrichment (SELEX) approach. Using a selection strategy that could generate aptamers for 2 pancreatic cancer cell lines in one selection scheme, we identified an aptamer SQ-2 that could recognize pancreatic cancer cells with high specificity. Next, by applying 2 alternative approaches: (i) aptamer-based target pull-down and (ii) genome-wide microarray-based identification of differentially expressed mRNAs in aptamer-positive and -negative cells, we identified alkaline phosphatase placental-like 2 (ALPPL-2), an oncofetal protein, as the target of SQ-2. ALPPL-2 was found to be ectopically expressed in many pancreatic cancer cell lines at both mRNA and protein levels. RNA interference-mediated ALPPL-2 knockdown identified novel tumor-associated functions of this protein in pancreatic cancer cell growth and invasion. In addition, the aptamer-mediated identification of ALPPL-2 on the cell surface and cell secretions of pancreatic cancer cells supports its potential use in the serum- and membrane-based diagnosis of PDAC.

Cited by

• Molecular Recognition of Human Liver Cancer Cells Using DNA Aptamers Generated via Cell-SELEX. [europepmc]
• Preparation and biomedical applications of programmable and multifunctional DNA nanoflowers. [europepmc]
• DNA methylation changes of whole blood cells in response to active smoking exposure in adults: a systematic review of DNA methylation studies. [europepmc]
• Isolation of an Aptamer that Binds Specifically to E. coli. [europepmc]
• Improving vascular maturation using noncoding RNAs increases antitumor effect of chemotherapy. [europepmc]
• Development of Cell-SELEX Technology and Its Application in Cancer Diagnosis and Therapy. [europepmc]
• Molecular Elucidation of Disease Biomarkers at the Interface of Chemistry and Biology. [europepmc]
• Blind SELEX Approach Identifies RNA Aptamers That Regulate EMT and Inhibit Metastasis. [europepmc]
• Selection of Nucleic Acid Aptamers Targeting Tumor Cell-Surface Protein Biomarkers. [europepmc]
• Supramolecular aptamer nano-constructs for receptor-mediated targeting and light-triggered release of chemotherapeutics into cancer cells. [europepmc]
• Identification of Smoking-Associated Differentially Methylated Regions Using Reduced Representation Bisulfite Sequencing and Cell type-Specific Enhancer Activation and Gene Expression. [europepmc]
• Detection of Gram-negative bacterial outer membrane vesicles using DNA aptamers. [europepmc]
• ALPPL2 Is a Potential Diagnostic Biomarker for Pancreatic Cancer-Derived Extracellular Vesicles. [europepmc]
• Albumin-to-alkaline phosphatase ratio serves as a prognostic indicator in unresectable pancreatic ductal adenocarcinoma: a propensity score matching analysis. [europepmc]
• Aptamers Against Live Targets: Is In Vivo SELEX Finally Coming to the Edge? [europepmc]
• Specific Aptamer-Based Probe for Analyzing Biomarker MCP Entry Into Singapore Grouper Iridovirus-Infected Host Cells via Clathrin-Mediated Endocytosis. [europepmc]
• Aptamers: a novel targeted theranostic platform for pancreatic ductal adenocarcinoma. [europepmc]
• ALPPL2 Is a Highly Specific and Targetable Tumor Cell Surface Antigen. [europepmc]
• Extracellular Vesicles as Potential Biomarkers for Early Detection and Diagnosis of Pancreatic Cancer. [europepmc]
• Advances in Aptamer-Based Biomarker Discovery. [europepmc]
• Profiling Cancer Cells by Cell-SELEX: Use of Aptamers for Discovery of Actionable Biomarkers and Therapeutic Applications Thereof. [europepmc]
• The AHR target gene scinderin activates the WNT pathway by facilitating the nuclear translocation of β-catenin. [europepmc]
• Aptamer nucleotide analog drug conjugates in the targeting therapy of cancers. [europepmc]
• The application of Aptamer in biomarker discovery. [europepmc]
• Aggregation-Induced Emission Luminogen: Role in Biopsy for Precision Medicine. [europepmc]

Related

• Advances in pancreatic cancer research: Moving towards early detection
• A Novel Tool for the Accurate and Affordable Early Diagnosis of Pancreatic Cancer via Machine Learning and Bioinformatics
• Early screening and diagnosis strategies of pancreatic cancer: a comprehensive review
• Novel therapeutic targets for pancreatic cancer
• Therapeutic options for the management of pancreatic cancer